InterventionsHuman trial

Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist (HRS9531), in Obese Adults without Diabetes—Up to 52-Week Treatment

ADA Scientific Sessions 2025 Abstract

The paper

Lin Zhao, Dan Zhu, Tianrong Pan,
Show 11 more authorsDongji Wang, Hongwei Ling, Ya Li, Cai H, Zhifeng Cheng, Dexue Liu, Yuan Hui, Xianfeng Zhang, Hong Chen, Yue Zuo, Yuqi Sun,
Xiaoying Li

Beijing

ADA Scientific Sessions 2025 Abstract · 13 Jun 2025

Presented at ADA Scientific Sessions 2025 · Poster 853-P

doi.org/10.2337/db25-853-p

Related